Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)
IntroductionPsoriasis localized at the scalp, face, nails, genitalia, palms, and soles can exacerbate the disease burden. Real-world studies comparing the effectiveness of treatments for these special areas are limited.MethodsPsoriasis Study of Health Outcomes (PSoHO) is an international, prospectiv...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1185523/full |
| _version_ | 1797792268846891008 |
|---|---|
| author | Stefano Piaserico Elisabeth Riedl Lev Pavlovsky Ronald B. Vender Can Mert Nithi Tangsirisap Natalie Haustrup Gaia Gallo Christopher Schuster Christopher Schuster Patrick M. Brunner |
| author_facet | Stefano Piaserico Elisabeth Riedl Lev Pavlovsky Ronald B. Vender Can Mert Nithi Tangsirisap Natalie Haustrup Gaia Gallo Christopher Schuster Christopher Schuster Patrick M. Brunner |
| author_sort | Stefano Piaserico |
| collection | DOAJ |
| description | IntroductionPsoriasis localized at the scalp, face, nails, genitalia, palms, and soles can exacerbate the disease burden. Real-world studies comparing the effectiveness of treatments for these special areas are limited.MethodsPsoriasis Study of Health Outcomes (PSoHO) is an international, prospective, non-interventional, study comparing the effectiveness of anti-interleukin (IL)-17A biologics (ixekizumab and secukinumab) compared to other approved biologics and the pairwise comparative effectiveness of ixekizumab relative to five other individual biologics for patients with moderate-to-severe psoriasis. To determine special area involvement, physicians answered binary questions at baseline and week 12. The proportion of patients who achieved special area clearance at week 12 was assessed. Missing outcome data were imputed as non-response. Comparative treatment analyses were conducted using frequentist model averaging.ResultsOf the 1,978 patients included, 83.4% had at least one special area involved at baseline with the scalp (66.7%) as the most frequently affected part, followed by nails (37.9%), face/neck (36.9%), genitalia (25.6%), and palms and/or soles (22.2%). Patients with scalp, nail, or genital, but not palmoplantar or face/neck psoriasis, had significantly higher odds of achieving clearance at week 12 in the anti-IL-17A cohort compared to the other biologics cohort. Patients with scalp psoriasis had a 10–20% higher response rate and significantly greater odds (1.8–2.3) of achieving clearance at week 12 with ixekizumab compared to included biologics.ConclusionBiologics demonstrate a high level of clearance of special areas at week 12 in a real-world setting. Patients with scalp, nail, or genital involvement have significantly higher odds of clearance at week 12 with anti-IL-17A biologics compared to other biologics. |
| first_indexed | 2024-03-13T02:30:46Z |
| format | Article |
| id | doaj.art-094ddb6e0fb942e5a4bf21fb560cbd4d |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-13T02:30:46Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-094ddb6e0fb942e5a4bf21fb560cbd4d2023-06-29T14:17:54ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-06-011010.3389/fmed.2023.11855231185523Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)Stefano Piaserico0Elisabeth Riedl1Lev Pavlovsky2Ronald B. Vender3Can Mert4Nithi Tangsirisap5Natalie Haustrup6Gaia Gallo7Christopher Schuster8Christopher Schuster9Patrick M. Brunner10Dermatology Unit, Department of Medicine, University of Padova, Padua, ItalyDepartment of Dermatology, Medical University of Vienna, Vienna, AustriaDepartment of Dermatology, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelDermatrials Research Inc. and Venderm Consulting, Hamilton, ON, CanadaHaaPACS GmbH, Schriesheim, GermanyEli Lilly and Company, Indianapolis, IN, United StatesEli Lilly and Company, Indianapolis, IN, United StatesEli Lilly and Company, Indianapolis, IN, United StatesDepartment of Dermatology, Medical University of Vienna, Vienna, AustriaEli Lilly and Company, Indianapolis, IN, United StatesDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, United StatesIntroductionPsoriasis localized at the scalp, face, nails, genitalia, palms, and soles can exacerbate the disease burden. Real-world studies comparing the effectiveness of treatments for these special areas are limited.MethodsPsoriasis Study of Health Outcomes (PSoHO) is an international, prospective, non-interventional, study comparing the effectiveness of anti-interleukin (IL)-17A biologics (ixekizumab and secukinumab) compared to other approved biologics and the pairwise comparative effectiveness of ixekizumab relative to five other individual biologics for patients with moderate-to-severe psoriasis. To determine special area involvement, physicians answered binary questions at baseline and week 12. The proportion of patients who achieved special area clearance at week 12 was assessed. Missing outcome data were imputed as non-response. Comparative treatment analyses were conducted using frequentist model averaging.ResultsOf the 1,978 patients included, 83.4% had at least one special area involved at baseline with the scalp (66.7%) as the most frequently affected part, followed by nails (37.9%), face/neck (36.9%), genitalia (25.6%), and palms and/or soles (22.2%). Patients with scalp, nail, or genital, but not palmoplantar or face/neck psoriasis, had significantly higher odds of achieving clearance at week 12 in the anti-IL-17A cohort compared to the other biologics cohort. Patients with scalp psoriasis had a 10–20% higher response rate and significantly greater odds (1.8–2.3) of achieving clearance at week 12 with ixekizumab compared to included biologics.ConclusionBiologics demonstrate a high level of clearance of special areas at week 12 in a real-world setting. Patients with scalp, nail, or genital involvement have significantly higher odds of clearance at week 12 with anti-IL-17A biologics compared to other biologics.https://www.frontiersin.org/articles/10.3389/fmed.2023.1185523/fullscalpfacepalmoplantarnailsgenitaliatreatment |
| spellingShingle | Stefano Piaserico Elisabeth Riedl Lev Pavlovsky Ronald B. Vender Can Mert Nithi Tangsirisap Natalie Haustrup Gaia Gallo Christopher Schuster Christopher Schuster Patrick M. Brunner Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO) Frontiers in Medicine scalp face palmoplantar nails genitalia treatment |
| title | Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO) |
| title_full | Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO) |
| title_fullStr | Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO) |
| title_full_unstemmed | Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO) |
| title_short | Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO) |
| title_sort | comparative effectiveness of biologics for patients with moderate to severe psoriasis and special area involvement week 12 results from the observational psoriasis study of health outcomes psoho |
| topic | scalp face palmoplantar nails genitalia treatment |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1185523/full |
| work_keys_str_mv | AT stefanopiaserico comparativeeffectivenessofbiologicsforpatientswithmoderatetoseverepsoriasisandspecialareainvolvementweek12resultsfromtheobservationalpsoriasisstudyofhealthoutcomespsoho AT elisabethriedl comparativeeffectivenessofbiologicsforpatientswithmoderatetoseverepsoriasisandspecialareainvolvementweek12resultsfromtheobservationalpsoriasisstudyofhealthoutcomespsoho AT levpavlovsky comparativeeffectivenessofbiologicsforpatientswithmoderatetoseverepsoriasisandspecialareainvolvementweek12resultsfromtheobservationalpsoriasisstudyofhealthoutcomespsoho AT ronaldbvender comparativeeffectivenessofbiologicsforpatientswithmoderatetoseverepsoriasisandspecialareainvolvementweek12resultsfromtheobservationalpsoriasisstudyofhealthoutcomespsoho AT canmert comparativeeffectivenessofbiologicsforpatientswithmoderatetoseverepsoriasisandspecialareainvolvementweek12resultsfromtheobservationalpsoriasisstudyofhealthoutcomespsoho AT nithitangsirisap comparativeeffectivenessofbiologicsforpatientswithmoderatetoseverepsoriasisandspecialareainvolvementweek12resultsfromtheobservationalpsoriasisstudyofhealthoutcomespsoho AT nataliehaustrup comparativeeffectivenessofbiologicsforpatientswithmoderatetoseverepsoriasisandspecialareainvolvementweek12resultsfromtheobservationalpsoriasisstudyofhealthoutcomespsoho AT gaiagallo comparativeeffectivenessofbiologicsforpatientswithmoderatetoseverepsoriasisandspecialareainvolvementweek12resultsfromtheobservationalpsoriasisstudyofhealthoutcomespsoho AT christopherschuster comparativeeffectivenessofbiologicsforpatientswithmoderatetoseverepsoriasisandspecialareainvolvementweek12resultsfromtheobservationalpsoriasisstudyofhealthoutcomespsoho AT christopherschuster comparativeeffectivenessofbiologicsforpatientswithmoderatetoseverepsoriasisandspecialareainvolvementweek12resultsfromtheobservationalpsoriasisstudyofhealthoutcomespsoho AT patrickmbrunner comparativeeffectivenessofbiologicsforpatientswithmoderatetoseverepsoriasisandspecialareainvolvementweek12resultsfromtheobservationalpsoriasisstudyofhealthoutcomespsoho |